Andrew Royer, OD
Optometrist · Saint Louis, MONPI 1255435657
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), consulting fees and education — rather than concentrated in one kind of arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.4%. 2025 is the largest year on record at $7,813, more than ten times the $722 reported in 2019. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 509 payments — averaging $46.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$5K
- AbbVie$3K
- Dompe US, Inc.$3K
- Tarsus Pharmaceuticals, Inc.$2K
- Sun Pharmaceutical Industries Inc.$1K
- Oyster Point Pharma, Inc.$1K
- plus $7K from 19 others
What the payments were for
- Consulting fees$9,38840%
- Speaking & faculty fees$530%
- Food & beverage$13,92459%
- Education$1000%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 31 | $5,480 |
| AbbVie(2 entities) | 122 | $3,268 |
| Dompe US, Inc. | 21 | $3,101 |
| Tarsus Pharmaceuticals, Inc. | 20 | $1,589 |
| Sun Pharmaceutical Industries Inc. | 38 | $1,384 |
| Oyster Point Pharma, Inc. | 27 | $1,373 |
| Biotissue Holdings Inc. | 22 | $1,191 |
| Novartis | 82 | $1,170 |
| Alcon | 27 | $1,159 |
| Glaukos Corporation | 11 | $628 |
| Harrow Eye, LLC | 31 | $613 |
| Kala Pharmaceuticals, Inc. | 20 | $585 |
| Mallinckrodt Hospital Products Inc. | 16 | $583 |
| Rxsight Inc | 6 | $348 |
| Amgen | 5 | $208 |
| Eyevance Pharmaceuticals LLC | 10 | $152 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $123 |
| Thea Pharma Inc. | 4 | $92 |
| UCB, Inc. | 1 | $90 |
| Johnson & Johnson Vision Care, Inc. | 3 | $84 |
| ANI Pharmaceuticals, Inc. | 3 | $77 |
| Tearlab Corp | 2 | $73 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $65 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$3,400
- Oxervate$2,476
- MIEBO$1,605
- TYRVAYA$870
- CEQUA$851
- TRYPTYR$551
- XIIDRA$462
- Prokera$441
- AmnioGraft$441
- XDEMVY$353
- iStent Inject Trabecular Micro-Bypass System$276
- INVELTYS$248
- GSW-iStentinjectWTrabecular Micro-Bypass System$138
- RXSIGHT CONTACT LENS$138
- RXSIGHT INJECTOR CARTRIDGE$138
- RXSIGHT INJECTOR HANDPIECE$138
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$138
- LIGHT ADJUSTABLE LENS (LAL)$138
- EYSUVIS$124
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$122
How this compares
$23,465 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 38 | $1,704,577 |
| XiidraLifitegrast | 368 | $426,853 |
| RestasisCyclosporine | 206 | $212,996 |
| XdemvyLotilaner | 96 | $186,176 |
| LumiganBimatoprost | 288 | $130,583 |
| MieboPerfluorohexyloctane/Pf | 101 | $93,796 |
| VevyeCyclosporine | 102 | $89,246 |
| CequaCyclosporine | 129 | $86,634 |
| TyrvayaVarenicline Tartrate | 66 | $44,232 |
| VyzultaLatanoprostene Bunod | 68 | $27,354 |
| Cyclosporine | 36 | $23,912 |
| Lotemax SmLoteprednol Etabonate | 74 | $22,383 |
| CombiganBrimonidine Tartrate/Timolol | 49 | $18,283 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 57 | $15,783 |
| EysuvisLoteprednol Etabonate | 17 | $9,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $3,101 | $1,704,57738 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $5,480 | $548,004537 claims |
| AbbVieRestasis, Lumigan, Combigan | $3,268 | $361,861543 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,589 | $186,17696 claims |
| Harrow Eye, LLCVevye | $613 | $89,246102 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,384 | $86,634129 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,373 | $44,23266 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Bepreve, Lotemax, Loteprednol Etabonate | $65 | $36,687118 claims |
| AlconSimbrinza | $1,159 | $15,78357 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $585 | $9,25617 claims |
| Eyevance Pharmaceuticals LLCFlarex, Tobradex St, Zerviate | $152 | $7,91045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Saint Louis
- John McGrealSaint Louis$126K
- Ariel CerenzieSaint Louis$76K
- Paul LuongSaint Louis$44K
- Robert EnsleySaint Louis$38K
- Robert BrusattiSaint Louis$20K
- Edward BennettSaint Louis$13K
- Craig SorceSaint Louis$8K
- Julie DekinderSaint Louis$8K
- Erin SullivanSaint Louis$6K
- Kathryn NoonanSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.